VRTXON

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

NavnVRTXON

RangeringNo.3709

Markedsverdi$0.00

Fullt utvannet markedsverdi$0.00

Markedsandel%

Handelsvolum/markedsgrense (24 timer)0.00%

Opplagsforsyning0.35953858

Maksimal forsyning0

Total forsyning0.35953858

Opplagsforsyning%

Utstedelsesdato--

Prisen for aktivaen da den først ble utstedt--

All-time high466.35223147502205,2026-03-26

Laveste pris432.04959348516377,2026-03-27

Offentlig blokkjedeETH

IntroduksjonVertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

Sektor

Sosiale medier

• Offisiell nettside
• Blokker Explorer

etfindex:mc_etfindex_sourceAnsvarsfraskrivelse: Dataene leveres av cmc og bør ikke betraktes som investeringsråd.